Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus 2024 per tanggal 11 Februari 2025 (1119 artikel)
Publikasi Scopus 2024 per tanggal 11 Februari 2025 (1119 artikel)
Lau, George (36114075400); Obi, Shuntaro (7005358917); Zhou, Jian (57218111894); Tateishi, Ryosuke (57221775871); Qin, Shukui (57217457374); Zhao, Haitao (8356306100); Otsuka, Motoyuki (7202038037); Ogasawara, Sadahisa (54397447400); George, Jacob (59192881500); Chow, Pierce K. H. (7202656968); Cai, Jianqiang (8835616900); Shiina, Shuichiro (7005392858); Kato, Naoya (7403474213); Yokosuka, Osamu (56063685300); Oura, Kyoko (57132346700); Yau, Thomas (23391533100); Chan, Stephen L. (34973871600);
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
2024
Hepatology International
18
6
1661
1683
22
2
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85209718693&doi=10.1007%2fs12072-024-10732-z&partnerID=40&md5=1be9166d1fef896d09458f7f8b8169e7
Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Zhongshan Hospital, Fudan University, Shanghai, Hong Kong; Department of Internal Medicine, Teikyo University Chiba Medical Center, Chiba, Japan; Department of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai Key Laboratory of Organ Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Cancer Centre of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China; Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, 700-8558, Japan; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8670, Japan; Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, 2145, NSW, Australia; Department of HPB Surgery and Transplantation, Duke-NUS Medical School, National Cancer Center Singapore and Singapore General Hospital, Surgery Academic Clinical Program, Singapore, Singapore; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Tokyo, Bunkyo-Ku, 113-8421, Japan; Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Kita, Kagawa, Miki, 761-0793, Japan; Department of Medicine, The University of Hong Kong, Hong Kong; Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong; Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China; Faculty of Medicine, Department of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan; Department of Liver Surgery, Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China; Department of OncologyDepartment of Medical OncologyGraduate Institute of OncologyDepartment of Internal Medicine, National Taiwan University Cancer CenterNational Taiwan University HospitalNational Taiwan University College of Medicine, Taipei, Taiwan; Humanity and Health Clinical Trial Center, Humanity & Health Medical Group, Hong Kong; Hepatobiliary Division, Department of Internal Medicine, and Hepatitis Center, Center for Infectious Disease and Cancer Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Medicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia; Department of Medical Oncology, Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore; Hepatobiliary Division, Staff Medic Group of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan; The Aga Khan University Hospital, Karachi, Pakistan; Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Department of Internal Medicine Division of Gastroenterology and Hepatology, Department of Internal MedicineHepatitis Research Center, Graduate Institute of Clinical Medicine, National Taiwan University Hospital Bei-Hu BranchNational Taiwan University HospitalNational Taiwan University College of Medicine, Taipei, Taiwan; Department of Surgery, Graduate School of Medicine, Hepato-Biliary-Pancreatic Surgery Division, The University of Tokyo, Tokyo, Japan; Department of Radiology, Seoul National University College of Medicine, Seoul, South Korea; Department of Medical Oncology, Peking University International Hospital, Beijing, China; Senior Department of Hepatology, The Fifth Medical Center of Chinese People’s Liberation, Army General Hospital, Beijing, China; Department of Comprehensive Liver Cancer Center, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China; Department of Medical Oncology, College of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China; Department of Medicine, Fatima University Medical Center, Manila, Philippines; Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh; Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China; European Liver Patients’ Association (ELPA), Brussels, Belgium; Department of Hepatobiliary, HCC Research Center for Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China; Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Section of Gastroenterology, University of Santo Tomas, Manila, Philippines; Department of Gastrointestinal Medical Oncology, Institute of Prevention and Treatment of Cancer of Heilongjiang Province, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China; Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Medicine, Ankara University School of Medicine, Ankara, Turkey; Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, China; Department of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Liver Surgery and Transplant Centre, Hong Kong Sanatorium and Hospital, Hong Kong; Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India; Department of Gastroenterology, Yamanashi Prefectural Center Hospital, Yamanashi, Kofu-City, Japan; Faculty of Health Science, Macau University, SAR, Macao; World Hepatitis Alliance, London, United Kingdom; African Liver Patient Association (ALPA), Cairo, Egypt; The Association of Liver Patients Care (ALPC), Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt
In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia–Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored? © Asian Pacific Association for the Study of the Liver 2024.
Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; ipilimumab; nivolumab; sorafenib; immune checkpoint inhibitor; ablation therapy; Article; body weight; confidence interval; disease exacerbation; drug efficacy; geographic distribution; hazard ratio; human; immunotherapy; liver cell carcinoma; liver transplantation; mortality; overall survival; practice guideline; progression free survival; systemic therapy; liver tumor; practice guideline; procedures; therapy
KUDO; Department of Gastroenterology and Hepatology; Kindai University of Medicine
We acknowledge the contributions of Professor Masatoshi KUDO (Department of Gastroenterology and Hepatology, Kindai University of Medicine, Osaka-Sayama, Osaka, Japan), Professor Masafumi IKEDA (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan) and Dr. Filza ASLAM (APAC Disease Area Network, HCC) for formulations of this CPG.
Springer
19360533
39570557
Article
Q1
1813
1622